Aldebaran Financial Inc. Abb Vie Inc. Transaction History

Aldebaran Financial Inc.

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 13, 2024	BUY	$159.82 - $182.1 $175,802 - $200,310	1,100 New	1,100 $200,000
Q2 2022 Aug 01, 2022	SELL	$137.62 - $174.96 $953,018 - $1.21 Million	-6,925 Reduced 70.13%	2,950 $450,000
Q1 2022 Apr 18, 2022	SELL	$131.98 - $163.75 $16,497 - $20,468	-125 Reduced 1.25%	9,875 $1.6 Million
Q4 2021 Feb 16, 2022	BUY	$107.43 - $135.93 $5,478 - $6,932	51 Added 0.51%	10,000 $1.35 Million
Q3 2021 Oct 21, 2021	BUY	$106.4 - $120.78 $23,088 - $26,209	217 Added 2.23%	9,949 $1.07 Million
Q2 2021 Jul 16, 2021	BUY	$105.21 - $117.21 $113,732 - $126,704	1,081 Added 12.5%	9,732 $1.11 Million
Q1 2021 May 03, 2021	BUY	$102.3 - $112.62 $30,690 - $33,786	300 Added 3.59%	8,651 $936,000
Q4 2020 Feb 05, 2021	BUY	$80.49 - $108.67 $241,550 - $326,118	3,001 Added 56.09%	8,351 $895,000
Q3 2020 Oct 19, 2020	BUY	$85.91 - $100.83 $20,188 - $23,695	235 Added 4.59%	5,350 $469,000
Q2 2020 Jul 20, 2020	SELL	$73.37 - $98.18 $470,301 - $629,333	-6,410 Reduced 55.62%	5,115 $502,000
Q1 2020 Apr 24, 2020	BUY	$64.5 - $97.79 $240,262 - $364,267	3,725 Added 47.76%	11,525 $878,000
Q4 2019 Feb 10, 2020	BUY	$72.13 - $90.25 $562,614 - $703,950	7,800 New	7,800 $691,000

3,699

1.27B

13M

9.79M

Ticker ABBV
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,768,099,968
Market Cap $344B
Description
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...

Get notified when there are updates to the investment portfolio of Aldebaran Financial Inc., based on Form 13F filings with the SEC.

Stay updated on Aldebaran Financial Inc. with notifications on news.